International Journal of Science and Technology

Eighth Edition

Volume 3, Issue 3

(Issue 8) (1-9) 2026

A Comprehensive Exploration of Pathogenesis, Epidemiology, Treatment, And Control of Shigellosis

Inas Ahmed Saeed

(Department of Microbiology/ College of Medicine / University of Babylon)

Published on: Published online on 4, August , 2026

Abstract :

Shigellosis is a highly contagious diarrheal illness caused by Shigella bacteria, posing a major global health challenge, particularly in regions with inadequate sanitation. The disease spreads primarily through the fecal-oral route, disproportionately affecting children under five and individuals with weakened immune systems. The pathogenesis of shigellosis involves the invasion and replication of Shigella within the colonic epithelium, resulting in intense inflammation and damage to the mucosal lining. Typical symptoms include diarrhea, fever, abdominal cramps, and dysentery. If left untreated, complications such as severe dehydration and hemolytic uremic syndrome can arise. A growing concern in the epidemiology of shigellosis is the rise of antimicrobial resistance, which complicates treatment options. Standard treatments involve rehydration and antibiotics like azithromycin and ciprofloxacin. However, the emergence of multidrug-resistant Shigella strains has underscored the urgent need for new antimicrobial therapies and effective vaccines. Current research is actively exploring alternative treatments to address resistant strains. Prevention and control strategies focus on improving sanitation, promoting hygiene practices such as handwashing, and advancing vaccination efforts. Public health initiatives are critical in reducing transmission by ensuring access to clean water, proper sanitation facilities, and health education. Given the escalating threat of drug resistance and the global impact of shigellosis, there is an urgent need for enhanced surveillance, innovative therapeutic approaches, and stronger prevention measures. Strengthening global health systems and intensifying research efforts are essential to reducing the prevalence of shigellosis, especially in endemic areas.

Keywords:

Shigellosis, *Shigella*, antimicrobial resistance, pathogenesis, epidemiology, treatment, prevention.

Introduction

Shigellosis, a highly contagious diarrheal disease caused by *Shigella* species, is a major public health concern, particularly in low- and middle-income countries with inadequate sanitation and limited access to clean water[1]. The disease is characterized by acute diarrhea, abdominal pain, fever, and dysentery, leading to significant morbidity and mortality, especially among young children, the elderly, and immunocompromised individuals. The *Shigella* genus comprises four major species: *S. dysenteriae, S. flexneri, S. boydii,* and *S. sonnei*, with *S. flexneri* being the most prevalent in developing nations and *S. sonnei* dominating in industrialized regions[2].

Transmission of *Shigella* occurs primarily through the fecal-oral route, often due to contaminated food, water, or direct person-to-person contact[3]. The bacteria exhibit remarkable adaptability, requiring a very low infectious dose (as few as 10–100 organisms) to cause disease, making outbreaks common in densely populated settings such as refugee camps, daycare centers, and healthcare facilities. The pathogenesis of *Shigella* involves its ability to invade and replicate within colonic epithelial cells, evade the host immune response, and induce severe inflammation, leading to intestinal damage and persistent diarrhea[4].

A significant challenge in shigellosis management is the rapid emergence of antimicrobial resistance (AMR). Resistance to first-line antibiotics, including ampicillin, trimethoprim-sulfamethoxazole, ciprofloxacin, and azithromycin, has become increasingly prevalent, complicating treatment options and necessitating the search for novel therapeutics. While supportive care and antimicrobial therapy remain the cornerstone of treatment, the growing prevalence of multidrug-resistant (MDR) *Shigella* strains has spurred efforts to develop effective vaccines[5].

This review provides a comprehensive exploration of the pathogenesis, epidemiology, treatment, and control measures of shigellosis. It highlights the global burden of the disease, the mechanisms underlying its pathogenicity, the challenges posed by antibiotic resistance, and the urgent need for improved prevention and control strategies. By understanding the complexities of *Shigella* infection, healthcare professionals and

researchers can develop more effective interventions to mitigate its impact, particularly in endemic regions[6].

Pathogenesis of Shigellosis

Shigellosis is caused by Shigella species, such as S. dysenteriae, S. flexneri, S. boydii, and S. sonnei. Of these, S. flexneri is the most common in developing countries. The disease develops through a sequence of key pathogenic mechanisms:

Invasion of the Intestinal Epithelium

Shigella primarily infects the colonic epithelium. The bacteria enter the body via contaminated food, water, or direct contact, eventually reaching the colon. They then invade the M cells of the intestinal mucosa, which act as an entry point into the deeper tissue layers[7].

Intracellular Replication and Spread

After crossing the intestinal barrier, Shigella is taken up by macrophages. Rather than being eliminated, the bacteria trigger macrophage apoptosis, releasing pro-inflammatory cytokines. This enables Shigella to invade epithelial cells, evade the immune system, and rapidly replicate within the host cells[8].

Actin-Based Motility and Cell-to-Cell Spread

Shigella exploits host actin filaments to move within and between cells, a strategy that helps it avoid detection by the immune system. This movement causes epithelial cell destruction, ulcer formation, and intense inflammation in the intestinal lining[9].

Toxin Production

Some Shigella species, notably S. dysenteriae, produce Shiga toxin. This toxin disrupts protein synthesis in host cells, leading to cell death and damage to small blood vessels. In severe cases, it can result in hemolytic uremic syndrome (HUS), a potentially fatal condition[10].

Severe Inflammation and Dysentery

The immune response to Shigella infection involves a massive influx of neutrophils, which contributes to significant tissue damage and shedding of the epithelial lining. This process causes the characteristic symptoms of shigellosis, including bloody diarrhea (dysentery) and severe abdominal cramps[11].

Epidemiology

Shigellosis remains a pressing global public health issue, particularly in regions where poor sanitation infrastructure and limited access to clean water persist. The disease disproportionately affects low- and middle-income countries, where healthcare resources are often scarce. Key epidemiological aspects of shigellosis include:

Global Burden

Shigellosis is estimated to affect around 125 million individuals worldwide each year. The highest burden of the disease is observed in sub-Saharan Africa and South Asia, where socioeconomic challenges and inadequate public health systems exacerbate its spread. Tragically, shigellosis is responsible for nearly 200,000 deaths annually, with the majority occurring among children under the age of five. This age group is particularly susceptible due to their underdeveloped immune systems and higher likelihood of exposure to contaminated environments[12].

Transmission

The primary mode of transmission for shigellosis is the fecal-oral route, which means the bacteria spread when fecal matter containing Shigella contaminates food, water, or surfaces, and is subsequently ingested. This can happen in several ways:

Contaminated Food and Water: Consuming food or water that has been contaminated with fecal matter containing Shigella is a common route of transmission. This often occurs in areas with inadequate sanitation, where sewage may mix with drinking water sources or where food is prepared or handled under unsanitary conditions.Direct Person-to-Person Contact: Shigellosis can also spread through direct contact with an infected individual, particularly in settings where hygiene practices are poor. For example, failing to wash hands properly after using the toilet or changing diapers can lead to the transfer of bacteria to surfaces, objects, or other people.Low Infectious Dose: Shigella is highly infectious, requiring only a small number of organisms (as few as 10–100) to cause infection. This low infectious dose makes it easier for the bacteria to spread, even with minimal exposure.Environmental Survival: Shigella can survive for extended periods in the environment, particularly in water, soil, or on surfaces, especially in warm and humid conditions. This ability to persist outside the human body further enhances its transmissibility.Overcrowded and Unsanitary Conditions: The risk of transmission is significantly higher in overcrowded environments, such as refugee camps, prisons, daycare centers, and urban slums, where access to clean water and proper sanitation is limited. In such settings, close contact between individuals and poor hygiene practices create ideal conditions for the rapid spread of the bacteria.The combination of a low infectious dose, environmental resilience, and the ease of transmission through multiple routes makes shigellosis exceptionally contagious and challenging to control. These factors highlight the critical importance of improving sanitation, ensuring access to clean water, and promoting hygiene practices like handwashing to prevent the spread of the disease.[13].

Risk Factors

Certain populations are at a heightened risk of contracting shigellosis. These include:

Young children, particularly those under five, due to their frequent hand-to-mouth behavior and exposure to contaminated environments.

Elderly individuals, who may have weakened immune systems.

Malnourished individuals, as malnutrition compromises the body's ability to fight infections.

People living in overcrowded or unsanitary conditions, such as refugee camps, prisons, and daycare centers, where close contact and poor hygiene facilitate the spread of the bacteria[14].

Antimicrobial Resistance (AMR)

A growing concern in the management of shigellosis is the rise of multidrug-resistant (MDR) Shigella strains. Over time, Shigella has developed resistance to several first-line antibiotics, including ampicillin, trimethoprim-sulfamethoxazole, ciprofloxacin, and azithromycin. This increasing resistance complicates treatment efforts, often leading to prolonged illness, higher healthcare costs, and greater morbidity and mortality. The emergence of MDR strains underscores the urgent need for alternative treatment options, improved antimicrobial stewardship, and the development of new therapeutic strategies.

shigellosis poses a significant threat to global health, particularly in resource-limited settings. Addressing this challenge requires a multifaceted approach, including improved sanitation, access to clean water, targeted vaccination programs, and robust public health interventions to curb transmission and mitigate the impact of antimicrobial resistance.

Treatment

Shigellosis is typically self-limiting, but in severe cases, medical intervention is required. Treatment strategies include:

1. **Supportive Care** –
    - **Rehydration Therapy** – Oral rehydration solutions (ORS) or intravenous fluids for severe dehydration.
    - **Nutritional Support** – Particularly important for malnourished children.
2. **Antibiotic Therapy** –
    - **Recommended Antibiotics** – Azithromycin, ciprofloxacin, ceftriaxone.
    - **Challenges with AMR** – Increasing resistance to fluoroquinolones and macrolides necessitates careful antibiotic selection based on local resistance patterns.
3. **Emerging Therapies** –
    - **New Antibiotic Development** – Novel agents such as zoliflodacin and gepotidacin are under investigation.
    - **Bacteriophage Therapy** – Potential alternative to combat MDR *Shigella* infections.

Control and Prevention

Effective control of shigellosis requires a multifaceted approach that includes public health interventions, improved sanitation, and vaccine development. Key strategies include:

1. **Sanitation and Hygiene** –
    - Improving access to clean water and sanitation facilities.
    - Promoting handwashing with soap, especially after using the toilet and before handling food.
    - Ensuring proper food handling and preparation.
2. **Public Health Measures** –
    - Surveillance programs to monitor outbreaks and antibiotic resistance patterns.
    - Public health education campaigns to raise awareness about transmission and prevention.
3. **Vaccine Development** –

- Several vaccine candidates are in development, including live attenuated, inactivated, and subunit vaccines.
- *S. flexneri* and *S. sonnei* are the primary targets for vaccine development due to their global prevalence[15].

4. **Antibiotic Stewardship** –
   - Rational antibiotic use to prevent the emergence of drug-resistant *Shigella* strains.
   - Development of alternative treatment strategies to reduce dependence on antibiotics[16].

Conclusion

Shigellosis remains a significant global health burden, with increasing challenges due to antimicrobial resistance. While supportive care and antibiotic therapy are the mainstay of treatment, the rise of MDR *Shigella* strains highlights the urgent need for novel therapeutics and vaccines. Preventative measures such as improved sanitation, hygiene promotion, and public health interventions are crucial to controlling the spread of the disease. Strengthening global surveillance and investing in vaccine research will be key to reducing the burden of shigellosis, particularly in endemic regions.

References

1-Scott, T. A., Baker, K. S., Trotter, C., Jenkins, C., Mostowy, S., Hawkey, J., ... & Baker, S. (2024). Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions. *Nature Reviews Microbiology*, 1-15.

2-Mohamed, S. P. (2024). A Comprehensive Exploration of Epidemiology, Pathogenesis, Treatment, and Control of Typhoid. *Today's Multidisciplinary Research Perspectives Volume-1*.

3-Bengtsson, R. J., Simpkin, A. J., Pulford, C. V., Low, R., Rasko, D. A., Rigden, D. J., ... & Baker, K. S. (2022). Pathogenomic analyses of Shigella isolates inform factors limiting shigellosis prevention and control across LMICs. *Nature microbiology*, *7*(2), 251-261.

4-Taneja, N., & Mewara, A. (2016). Shigellosis: epidemiology in India. *Indian Journal of Medical Research*, *143*(5), 565-576.

5-Mason, L. (2025). *The genomic epidemiology of antimicrobial resistant sexually transmissible shigellosis* (Doctoral dissertation, University of Liverpool).

6-Hossain, M. A., Al Amin, M., Khan, M. A., Refat, M. R. R., Sohel, M., Rahman, M. H., ... & Hoque, M. N. (2024). Genome-Wide Investigation Reveals Potential Therapeutic Targets in Shigella spp. *BioMed Research International*, *2024*(1), 5554208.
7-Tilahun, M., Belete, M. A., Gedefie, A., Debash, H., Alemayehu, E., Weldehana, D. G., ... & Shibabaw, A. (2025). Prevalence of Salmonella and Shigella species and their multidrug resistance patterns among pediatric populations in Ethiopia: a systematic review and meta-analysis. *BMC Infectious Diseases*, *25*(1), 52.
8-Edward, S. (2024). A fractional order model for the transmission dynamics of shigellosis. *Heliyon*, *10*(10).
9-Kaltsas, A., Giannakodimos, I., Markou, E., Adamos, K., Stavropoulos, M., Kratiras, Z., ... & Chrisofos, M. (2025). The Role of Gut Microbiota Dysbiosis in Erectile Dysfunction: From Pathophysiology to Treatment Strategies. *Microorganisms*, *13*(2), 250.
10-Chen, Q., Yang, T., Wu, P., Liu, Q., Wu, F., Shi, H., ... & Wu, W. (2024). From Environmental Exposure Risk to Epigenetic Factors: What Role Do They Play in the Etiology of Endometriosis?.
11-Berihu, T., Gebremariam, G., Weldu, Y., Kahsay, A., Asmelash, T., & Gebreyesus, A. (2024). Muzembo, B. A., Kitahara, K., Mitra, D., Ohno, A., Khatiwada, J., Dutta, S., & Miyoshi, S. I. (2023). Shigellosis in Southeast Asia: A systematic review and meta-analysis. *Travel Medicine and Infectious Disease*, *52*, 102554.
12-Boppana, K., Almansouri, N. E., Bakkannavar, S., Faheem, Y., Jaiswal, A., Shergill, K., & Nath, T. S. (2024). Alterations in Gut Microbiota as Early Biomarkers for Predicting Inflammatory Bowel Disease Onset and Progression: A Systematic Review. *Cureus*, *16*(4).
13-Uddin, M. N., Khan, W., Qayum, N., Taj-Ud-Din, D. N., Qayum, S., Wadood, J., ... & Zaman, N. (2023). Shigellosis; a clinical perspective. *Zoonosis, Unique Scientific Publishers, Faisalabad, Pakistan*, *4*, 544-556.
14-Matanza, X. M., & Clements, A. (2023). Pathogenicity and virulence of Shigella sonnei: a highly drug-resistant pathogen of increasing prevalence. *Virulence*, *14*(1), 2280838..
15-Bazhenova, A., Gao, F., Bolgiano, B., & Harding, S. E. (2021). Glycoconjugate vaccines against Salmonella enterica serovars and Shigella species: existing and emerging methods for their analysis. *Biophysical Reviews*, *13*(2), 221-246.